Neue Entwicklungen in der Therapie des Diabetes mellitus Typ 2

Die rasante Entwicklung der Diabetesforschung hat viele neue Medikamente und Therapiestrategien auf den Weg gebracht, die das Potenzial haben, auch unabhängig von einer Diabeteserkrankung wirksam zu sein. So gibt es neue Erkenntnisse zu SGLT-2-Inhibitoren bei Herz- und chronischer Niereninsuffizienz. Auch die Weiterentwicklung inkretinbasierter Medikamente und duale GIP/GLP-1-Rezeptoragonisten sind vielversprechend.

Abstract

Diabetes mellitus has become a widespread disease worldwide. In recent years, there has been a rapid development of therapeutic options in the field of diabetology. Many new drugs and therapeutic strategies are now available or will be available in the near future, which have the potential to significantly improve the care of patients even if they do not have diabetes. In this article, we would like to present the latest therapeutic options and possible further applications. The article focuses, among other things, on the new findings of SGLT-2-inhibitors in cardiac and chronic renal failure and the further development of incretin-based drugs toward dual GIP/GLP-1-receptor agonists. Once-weekly insulin and the selective mineralocorticoid receptor antagonist finerenone will also be presented.

Schlüsselwörter

Diabetes mellitus Typ 2 - GLP-1- Rezeptoragonisten - SGLT-2-Inhibitoren - Insulin Icodec - Finerenon

Key words

type 2 diabetes mellitus - GLP-1 receptor agonist - SGLT-2-inhibitors - insulin icodec - finerenone

Publication History

Article published online:
11 May 2022

• Literatur

• 1 International Diabetes Federation IDF Diabetes Atlas. 9. Aufl.. Brüssel: IDF; 2019
• 2 Jacobs E, Hoyer A, Brinks R. et al. Burden of Mortality Attributable to Diagnosed Diabetes: A Nationwide Analysis Based on Claims Data From 65 Million People in Germany. Diabetes Care 2017; 40: 1703-1709
• 3 Deutsche Diabetes Gesellschaft (DDG). Deutscher Gesundheitsbericht Diabetes. Berlin: DDG; 2021
• 4 Nichols GA, Gullion CM, Koro CE. et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879-1884
• 5 Go AS, Chertow GM, Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
• 6 Weckmann G, Stracke S, Chenot J. DEGAM S3-Leitlinie Nr. 22: Versorgung von Patienten mit chronischer nicht-dialysepflichtiger Nierenerkrankung in der Hausarztpraxis. AWMF-Register-Nr. 053-048. Stand: 2019
• 7 Wiviott S, Raz I, Bonaca MP. et al. Dapagliflozin and Cardiovascular outcomes in Type 2 Diabetes. N Engl J Med 2019; 380: 347-357
• 8 Wanner C, Inzucchi SE, Lachin JM. et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334
• 9 Cannon CP, Pratley R, Dagogo-Jack S. et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383 (15) 1425-1435
• 10 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008
• 11 Packer M, Anker SD, Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-1424
• 12 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385: 1451-1461
• 13 Heerspink HJ, Stefánsson BV, Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2019; 383: 1436-1446
• 14 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322
• 15 Gerstein GC, Colhoun HM, Dagenais GR. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130
• 16 Marso SP, Bain SC, Consoli A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844
• 17 Pratley RE, Aroda VR, Lingvay I. et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018; 6 (04) 275-286
• 18 Lingvay I, Bauer R, Baker-Knight J. et al An indirect treatment comparison of semaglutide 2.0 mg versus dulaglutide 3.0 mg and 4.5 mg using multi-level network meta-regression. J Clin Endocrinol Metab 2021; . Online ahead of print
• 19 EMA. Rybelsus® Summary of Product Characteristics. Im Internet (Stand: 03.02.2022): https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf
• 20 Eliaschewitz FG, Canani LH. Advances in GLP-1 treatment: focus on oral semaglutide. Diabetol Metab Syndr 2021; 13 (01) 99
• 21 Wilding JPH, Batterham RL, Calanna S. et al. Once-weekly Semaglutide in adults with oberweight or obesity. N Engl J Med 2021; 384: 989-1002
• 22 Frias PJ, Davies MJ, Rosenstock J. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385 (06) 503-515
• 23 Lingvay I, Buse JB, Franek E. et al. A randomized, open-label Comparison of once-weekly Insulin Icodec Titration Strategies versus once-daily Insulin glargine U100. Diabetes Care 2021; 44 (07) 1595-1603
• 24 Bakris GL, Agarwal R, Anker SD. et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383 (23) 2219-2229
• 25 Pitt B, Filippatos G, Agarwal R. et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385: 2252-2263
• 26 Harger A, Stemmer K, Tschöp MH. et al. Incretin-based co- and tri-agonists: Innovative pholypharmacology for the treatment of obesity and diabetes. Internist (Berl) 2019; 60 (09) 895-902
• 27 Ärztliche Zentrum für Qualität in der Medizin. Nationale Versorgunsleitlinie Typ-2-Diabetes, Leitlinienreport. 2. Aufl. AWMF-Register-Nr. nvl-001. Stand: 2021
• 28 Landgraf R, Aberle J, Birkenfeld AL. et al. Therapie des Typ-2-Diabetes. Diabetologie und Stoffwechsel 2021; 16 (Suppl. 02) S168-S206